Profile data is unavailable for this security.
About the company
PeptiDream Inc. is a Japan-based bio-venture company started by the University of Tokyo and principally engaged in the discovery and development of non-standard peptide therapeutics. The Company operates the Peptide Discovery Platform System (PDPS), a drug development platform system and conducts research and development (R&D) on new drug candidates based on the joint R&D with pharmaceutical companies in Japan and overseas. The Company is involved in the business centered on drug development based on special peptides. The Company's businesses include drug discovery joint R&D, PDPS technology loan (PDPS technology license) and expansion of its own pipeline through strategic alliance (strategic alliance or in-house drug discovery).
- Revenue in JPY (TTM)55.42bn
- Net income in JPY21.69bn
- Incorporated2006
- Employees603.00
- LocationPeptiDream Inc3-25-23, Tono-machi, Kawasaki-kuKAWASAKI-SHI 210-0821JapanJPN
- Phone+81 442701300
- Websitehttps://www.peptidream.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mabwell Shanghai Bioscience Co Ltd | 3.24bn | -22.91bn | 233.11bn | 1.40k | -- | 5.09 | -- | 71.97 | -2.71 | -2.71 | 0.3839 | 5.43 | 0.0333 | 0.0737 | 5.27 | 102,885.50 | -23.65 | -37.61 | -28.84 | -45.95 | 92.64 | 81.54 | -709.97 | -2,112.26 | 1.63 | -243.33 | 0.4853 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
Keymed Biosciences Inc | 1.72bn | -15.69bn | 250.08bn | 1.12k | -- | 4.49 | -- | 145.03 | -3.15 | -3.15 | 0.3456 | 10.43 | 0.0207 | 0.3115 | 7.74 | 100,739.50 | -18.86 | -- | -20.96 | -- | 68.65 | -- | -909.38 | -- | 4.83 | -- | 0.2155 | -- | 253.87 | -- | -16.63 | -- | -- | -- |
Ascentage Pharma Group International | 19.07bn | -7.61bn | 252.28bn | 574.00 | -- | 15.56 | -- | 13.23 | -1.38 | -1.38 | 3.44 | 2.70 | 0.2998 | 3.49 | 2.19 | 1,714,167.00 | -11.97 | -44.93 | -16.78 | -57.04 | 96.96 | 87.68 | -39.93 | -976.10 | 1.83 | -8.16 | 0.6865 | -- | 5.85 | 100.76 | -4.84 | -- | 2.82 | -- |
Clarity Pharmaceuticals Ltd | 0.00 | -4.24bn | 252.56bn | -- | -- | 16.81 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
Joinn Laboratories China Co Ltd | 46.74bn | 2.88bn | 271.97bn | 2.59k | 97.74 | 1.71 | -- | 5.82 | 0.1847 | 0.1847 | 2.97 | 10.56 | 0.2227 | 0.7454 | 7.65 | -- | 1.31 | 8.99 | 1.58 | 11.07 | 36.70 | 46.76 | 5.86 | 32.01 | 2.54 | 2.57 | 0.0071 | 23.81 | 4.78 | 42.20 | -63.04 | 29.66 | 8.21 | 23.46 |
InnoCare Pharma Ltd | 16.49bn | -9.94bn | 286.05bn | 1.11k | -- | 1.72 | -- | 17.35 | -0.3085 | -0.3085 | 0.5115 | 4.34 | 0.0786 | 0.9875 | 3.19 | 793,397.30 | -4.88 | -13.41 | -6.20 | -15.36 | 85.59 | 85.99 | -62.04 | -172.16 | 3.77 | -- | 0.1667 | -- | 18.09 | 240.36 | 28.80 | -- | 66.20 | -- |
RemeGen Co Ltd | 29.49bn | -33.54bn | 341.70bn | 3.50k | -- | 4.01 | -- | 11.59 | -3.27 | -3.27 | 2.87 | 5.42 | 0.2411 | 0.4413 | 6.06 | 427,581.40 | -27.42 | -18.66 | -35.04 | -23.75 | 77.11 | 81.94 | -113.72 | -102.88 | 1.06 | -31.41 | 0.4737 | -- | 40.16 | 148.65 | -51.30 | -- | 59.07 | -- |
Peptidream Inc | 55.42bn | 21.69bn | 371.63bn | 603.00 | 17.10 | 6.30 | 15.45 | 6.71 | 167.15 | 167.15 | 427.44 | 453.44 | 0.7217 | 4.49 | 2.97 | 91,906,740.00 | 28.25 | -- | 33.81 | -- | 77.98 | -- | 39.14 | -- | 3.23 | 14.72 | 0.2626 | -- | 6.93 | -- | -59.81 | -- | -- | -- |
Dizal Jiangsu Pharmaceutical Co Ltd | 6.23bn | -19.81bn | 384.56bn | 581.00 | -- | 29.91 | -- | 61.78 | -2.29 | -2.29 | 0.7174 | 1.47 | 0.1742 | 0.4174 | 4.62 | 507,467.80 | -60.62 | -46.02 | -81.84 | -52.99 | 96.75 | 57.53 | -347.91 | -2,081.54 | 1.81 | -- | 0.5253 | -- | -- | 18.29 | -50.50 | -- | 21.35 | -- |
Sinocelltech Group Ltd | 50.33bn | -2.80bn | 388.89bn | 2.33k | -- | -- | -- | 7.73 | -0.2974 | -0.2974 | 5.35 | -1.03 | 0.818 | 0.4037 | 5.81 | 1,021,836.00 | -4.55 | -40.17 | -13.68 | -74.63 | 96.26 | 95.42 | -5.56 | -108.20 | 0.5057 | 4.62 | 1.19 | -- | 84.46 | 264.19 | 23.70 | -- | 37.54 | -- |
Holder | Shares | % Held |
---|---|---|
M&G Investment Management Ltd.as of 15 Dec 2023 | 9.80m | 7.54% |
Taiyo Pacific Partners LPas of 31 Dec 2023 | 6.58m | 5.06% |
Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 14 Jul 2023 | 4.44m | 3.42% |
Baillie Gifford & Co.as of 31 Jul 2024 | 3.28m | 2.52% |
Nomura Asset Management Co., Ltd.as of 31 May 2024 | 3.24m | 2.50% |
The Vanguard Group, Inc.as of 04 Jul 2024 | 3.09m | 2.37% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.09m | 1.61% |
Nikko Asset Management Co., Ltd.as of 14 Jul 2023 | 1.80m | 1.39% |
Daiwa Asset Management Co. Ltd.as of 28 Jun 2024 | 1.54m | 1.18% |
Alma Capital Investment Management SA (UK)as of 31 Dec 2023 | 1.36m | 1.05% |